ifa systems AG

  • WKN: 783078
  • ISIN: DE0007830788
  • Land: Deutschland

Nachricht vom 04.06.2019 | 10:50

ifa systems AG: Nexus AG acquires majority participation in ifa systems AG from Topcon

ifa systems AG / Key word(s): Investment
ifa systems AG: Nexus AG acquires majority participation in ifa systems AG from Topcon

04-Jun-2019 / 10:50 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The majority shareholder of ifa systems AG, Topcon Europe Medical B.V., has informed the management board that it has entered into a share purchase agreement on the disposal of its participation in ifa systems AG amounting to approx. 52.56 % of the share capital with Nexus AG having its seat in Donaueschingen. The share purchase agreement will be consummated by 5 June 2019 the latest. The loans granted to ifa systems AG by Topcon in the amount of EUR 4m will be assumed by Nexus AG in the amount of EUR 3m and repaid by ifa systems AG in the amount of EUR 1m. Such repayment will not reduce the cash since it will be set-off against payment claims of ifa group against Topcon. In the course of the transaction, the supervisory board members Nick Smit and Randy Samuels as well as the management board member Nobuo Takase will also resign from their offices by 5 June 2019 the latest with immediate effect. The management board will apply for the appointment of two new supervisory board members by court at short notice.

Contact (informing person):

Jörg Polis
Chairman of the Management Board

04-Jun-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021